Cargando…

The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trials

PURPOSE: We aimed at assessing the overall efficacy of angiogenesis inhibitor (AI)-containing regimens in the treatment of advanced non-small-cell lung cancer (NSCLC) according to histological types. METHODS: Studies from PubMed and Web of Science, and abstracts presented at American Society of Clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jian, Liu, Jie, Chen, Huiguo, Wu, Weibin, Li, Xiaojun, Wu, Yonghui, Zhang, Kai, Gu, Lijia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562761/ https://www.ncbi.nlm.nih.gov/pubmed/26366091 http://dx.doi.org/10.2147/OTT.S90407

Ejemplares similares

An operated case of locally advanced thymic atypical carcinoid in anterior mediastinum: a case report
por: Zhang, Kai, et al.
Publicado: (2020)

Myeloid and plasmacytoid dendritic cell combined vaccines loaded with heat-treated tumor cell lysates enhance antitumor activity in murine lung cancer
por: Chen, Huiguo, et al.
Publicado: (2021)

Rare diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: one case report and literature review
por: Wu, Yonghui, et al.
Publicado: (2020)

Organizing pneumonia in ALK+ lung adenocarcinoma treated with ceritinib: A case report and literature review
por: Wu, Yonghui, et al.
Publicado: (2021)

Recurrent transmural tracheal schwannoma resected by video-assisted thoracoscopic window resection: A case report
por: Chen, Huiguo, et al.
Publicado: (2019)

Angiogenesis Inhibitors in NSCLC
por: Manzo, Anna, et al.
Publicado: (2017)

Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review
por: Wu, Yonghui, et al.
Publicado: (2021)

Rare chondroblastoma of the 6th left rib, video-assisted thoracoscopy resected: one case report and literature review
por: Wu, Yonghui, et al.
Publicado: (2021)

Multiple bronchiolar adenomas with malignant transformation and CCNE1 mutation: a case report and literature review
por: Li, Xiaojun, et al.
Publicado: (2021)

Efficacy and Safety Analysis of Immune Checkpoint Inhibitors plus Angiogenesis Inhibitors for the Treatment of Advanced Driver-negative NSCLC in Elderly Patients: A Retrospective Study
por: Zhang, Jian, et al.
Publicado: (2023)

Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis
por: Yu, Jing, et al.
Publicado: (2016)

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis
por: Dafni, U., et al.
Publicado: (2022)

Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
por: ZHANG, JIAN, et al.
Publicado: (2012)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
por: Wang, Yang, et al.
Publicado: (2021)

Overexpression of Wnt5a Promotes Angiogenesis in NSCLC
por: Yao, Lingli, et al.
Publicado: (2014)

The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis
por: Zhang, Chunmei, et al.
Publicado: (2022)

Development of a novel thymidylate synthase (TS) inhibitor capable of up-regulating P53 expression and inhibiting angiogenesis in NSCLC
por: Li, Xin-yang, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
por: Qian, Xiaoyu, et al.
Publicado: (2022)

The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis
por: Zhou, Liang, et al.
Publicado: (2016)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC
por: Hu, Rong, et al.
Publicado: (2020)

The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis
por: Fan, Junsheng, et al.
Publicado: (2018)

Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis
por: Kim, Jinchul, et al.
Publicado: (2018)

High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC
por: Ye, Dafu, et al.
Publicado: (2023)

Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study
por: Liang, Jianmiao, et al.
Publicado: (2020)

Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly
por: Wu, Chunrong, et al.
Publicado: (2018)

The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR
por: Zhou, Yanhua, et al.
Publicado: (2022)

TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
por: Qin, Jiqiu, et al.
Publicado: (2023)

Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
por: Coelho, Ana Luísa, et al.
Publicado: (2016)

Controversial role of mast cells in NSCLC tumor progression and angiogenesis
por: Longo, Vito, et al.
Publicado: (2022)

Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced non-small-cell lung cancer: A systematic review and meta-analysis
por: Chen, Zhaoxin, et al.
Publicado: (2020)

Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD‐1 inhibitor therapy
por: Fang, Qiyu, et al.
Publicado: (2022)

Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis
por: Li, Feng, et al.
Publicado: (2022)

Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC: A Meta-Analysis
por: Chen, Zhenguang, et al.
Publicado: (2015)

Immunotherapeutic Advances for NSCLC
por: Massafra, Marco, et al.
Publicado: (2021)

A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
por: Lu, Yue, et al.
Publicado: (2021)

Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis
por: Li, Wenjie, et al.
Publicado: (2023)

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study
por: Yang, Guangjian, et al.
Publicado: (2022)

Efficacy and safety of anti-angiogenesis medicines for advanced soft tissue sarcoma: a meta-analysis
por: Wang, Yuxuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3i1728a5hm6gm8i5re05f74jfu